NASDAQ:SRPT - Sarepta Therapeutics Stock Price, Forecast & News

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Sarepta Therapeutics Inc (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, February, 26th. The biotechnology company reported ($3.16) EPS for the quarter, missing the Zacks' consensus estimate of ($1.86) by $1.30. The biotechnology company earned $100.11 million during the quarter, compared to the consensus estimate of $100.10 million. Sarepta Therapeutics had a negative net margin of 187.77% and a negative return on equity of 62.31%. During the same period in the previous year, the business posted ($2.05) EPS. View Sarepta Therapeutics' Earnings History.

Sarepta Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Sarepta Therapeutics.

25 equities research analysts have issued 1-year price targets for Sarepta Therapeutics' stock. Their forecasts range from $160.00 to $260.00. On average, they expect Sarepta Therapeutics' share price to reach $197.00 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price. View Analyst Price Targets for Sarepta Therapeutics.

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 hold rating and 24 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sarepta Therapeutics.

Media headlines about SRPT stock have been trending positive on Friday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sarepta Therapeutics earned a daily sentiment score of 2.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Sarepta Therapeutics.

Sarepta Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 12,660,000 shares, an increase of 6.3% from the January 15th total of 11,910,000 shares. Based on an average trading volume of 1,322,000 shares, the days-to-cover ratio is presently 9.6 days. Currently, 17.9% of the shares of the company are short sold. View Sarepta Therapeutics' Current Options Chain.

Some companies that are related to Sarepta Therapeutics include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Genmab A/S (GNMSF), Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN) and Mylan (MYL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Advanced Micro Devices (AMD), Tesla (TSLA), ACADIA Pharmaceuticals (ACAD) and Bausch Health Companies (BHC).

Sarepta Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sands Capital Management LLC (6.11%), Janus Henderson Group PLC (4.25%), Capital Research Global Investors (3.23%), Fred Alger Management LLC (1.16%), Geode Capital Management LLC (1.06%) and Jennison Associates LLC (1.03%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme. View Institutional Ownership Trends for Sarepta Therapeutics.

SRPT stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, FIL Ltd, Cadian Capital Management LP, Point72 Asset Management L.P., Jennison Associates LLC, Boxer Capital LLC, Casdin Capital LLC and Alyeska Investment Group L.P.. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, David T Howton, Hans Lennart Rudolf Wigzell and Sandesh Mahatme. View Insider Buying and Selling for Sarepta Therapeutics.

SRPT stock was purchased by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Janus Henderson Group PLC, Sands Capital Management LLC, Bessemer Group Inc., Kam Lawrence, California Public Employees Retirement System, UBS Asset Management Americas Inc. and Marshall Wace North America L.P.. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, M Kathleen Behrens, Michael W Bonney and Richard Barry. View Insider Buying and Selling for Sarepta Therapeutics.

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SRPT stock can currently be purchased for approximately $114.47.

Sarepta Therapeutics has a market capitalization of $8.53 billion and generates $380.83 million in revenue each year. The biotechnology company earns $-361,920,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis. Sarepta Therapeutics employs 499 workers across the globe.View Additional Information About Sarepta Therapeutics.

The official website for Sarepta Therapeutics is http://www.sareptatherapeutics.com/.

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]